These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 36980649)

  • 41. Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
    Kappel C; Elliott MJ; Kumar V; Nadler MB; Desnoyers A; Amir E
    Sci Rep; 2024 Feb; 14(1):3129. PubMed ID: 38326452
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.
    Parati MC; Pedersini R; Perego G; Reduzzi R; Savio T; Cabiddu M; Borgonovo K; Ghilardi M; Luciani A; Petrelli F
    Breast Cancer (Dove Med Press); 2022; 14():101-111. PubMed ID: 35440873
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CDK4/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: A real-world and propensity score-adjusted comparison.
    Coutinho-Almeida J; Silva AS; Redondo P; Rodrigues PP; Ferreira A
    Cancer Treat Res Commun; 2024; 40():100818. PubMed ID: 38761788
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences.
    Johnston S; Emde A; Barrios C; Srock S; Neven P; Martin M; Cameron D; Janni W; Gnant M
    JNCI Cancer Spectr; 2023 Jul; 7(4):. PubMed ID: 37369022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis.
    Mastrantoni L; Orlandi A; Palazzo A; Garufi G; Fabi A; Daniele G; Giannarelli D; Tortora G; Bria E
    EClinicalMedicine; 2023 Feb; 56():101824. PubMed ID: 36713467
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of Cardiovascular Events with Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) Inhibitors among Patients with Advanced Breast Cancer: A Systematic Review and Network Meta-Analysis.
    Liu YS; Dong K; Park C
    Rev Cardiovasc Med; 2023 Nov; 24(11):309. PubMed ID: 39076428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer.
    Echavarria I; Jerez Y; Martin M; López-Tarruella S
    Breast Care (Basel); 2017 Oct; 12(5):296-302. PubMed ID: 29234248
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
    Sammons SL; Topping DL; Blackwell KL
    Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-positive Breast Cancer and Alternative Treatment Strategies.
    Chang CM; Lam HYP
    Anticancer Res; 2023 Dec; 43(12):5283-5298. PubMed ID: 38030174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?
    Ploumaki I; Triantafyllou E; Koumprentziotis IA; Karampinos K; Drougkas K; Karavolias I; Kotteas E
    Clin Breast Cancer; 2024 Apr; 24(3):e177-e185. PubMed ID: 38320891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CDK 4/6 inhibitors for adjuvant therapy in early breast cancer-Do we have a clear winner?
    Akhade A; Van Wambeke S; Gyawali B
    Ecancermedicalscience; 2022; 16():ed124. PubMed ID: 36200010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study.
    Lin W; Zeng Y; Weng L; Yang J; Zhuang W
    BMC Pharmacol Toxicol; 2024 Aug; 25(1):47. PubMed ID: 39123221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.
    Hecht KA; Selby C
    Ann Pharmacother; 2019 Feb; 53(2):195-203. PubMed ID: 30079740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives.
    Roberto M; Astone A; Botticelli A; Carbognin L; Cassano A; D'Auria G; Fabbri A; Fabi A; Gamucci T; Krasniqi E; Minelli M; Orlandi A; Pantano F; Paris I; Pizzuti L; Portarena I; Salesi N; Scagnoli S; Scavina P; Tonini G; Vici P; Marchetti P
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477469
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.
    George MA; Qureshi S; Omene C; Toppmeyer DL; Ganesan S
    Front Oncol; 2021; 11():693104. PubMed ID: 34327137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness of the addition of CDK4/6 inhibitors to standard endocrine therapy in first-line treatment of women with advanced HR+/HER2- breast cancer in Mexico.
    Molina-Jaimes M; Galindo-González A; Verduzco-Aguirre HC; Bautista-Arredondo S; Reyes-Terán G; Soto-Perez-de-Celis E
    Clin Transl Oncol; 2024 Jan; 26(1):239-244. PubMed ID: 37329428
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
    Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
    Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of abemaciclib in treatment of advanced breast cancer.
    McCartney A; Moretti E; Sanna G; Pestrin M; Risi E; Malorni L; Biganzoli L; Di Leo A
    Ther Adv Med Oncol; 2018; 10():1758835918776925. PubMed ID: 29899762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CDK4/6 inhibition in early and metastatic breast cancer: A review.
    de Groot AF; Kuijpers CJ; Kroep JR
    Cancer Treat Rev; 2017 Nov; 60():130-138. PubMed ID: 28961554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Latest Overview of the Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: The Past, the Present and the Future.
    Chen X; Xu D; Li X; Zhang J; Xu W; Hou J; Zhang W; Tang J
    J Cancer; 2019; 10(26):6608-6617. PubMed ID: 31777590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.